This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: high-density lipoprotein (HDL)-cholesterol

January 2023 Br J Cardiol 2023;30:31–4 doi:10.5837/bjc.2023.005

The prognostic impact of HDL-C level in patients presenting with ST-elevation myocardial infarction

Ahmed Mahmoud El Amrawy, Abdallah Almaghraby, Mahmoud Hassan Abdelnabi

Abstract

Introduction Multiple risk factors have been identified for myocardial infarction (MI). Hypercholesterolaemia is one of the major risk factors for cardiovascular diseases, and has an important pathophysiological role in the development of acute ST-elevation myocardial infarction (STEMI).1 Endothelial dysfunction, inflammation, increased thrombogenicity, and plaque vulnerability are the main underlying mechanisms explaining the complex interaction between hypercholesterolaemia and STEMI.2–4 Low-density lipoprotein-cholesterol (LDL-C) has been shown to be a major risk factor in patients with MI, and aggressive LDL-C lowering remains a main ta

| Full text
News from ESC 2018: Not all HDL cholesterol is cardioprotective

October 2018 Br J Cardiol 2018;25:135–7

News from ESC 2018: Not all HDL cholesterol is cardioprotective

BJC Staff

Abstract

European Society of Cardiology congress 2018, held in Munich This study, conducted as part of the Emory Cardiovascular Biobank, investigated the relationship between HDL cholesterol levels and the risk of heart attack and death in 5,965 individuals, most of whom had heart disease. The average age of participants was 63 years and 35% were female. Participants were divided into five groups according to their HDL cholesterol level: less than 30 mg/dl (0.78 mmol/L), 31–40 mg/dl (0.8–1 mmol/L); 41–50 mg/dl (1.1–1.3 mmol/L); 51–60 mg/dl (1.3–1.5 mmol/L); and greater than 60 mg/dl (1.5 mmol/L). During a median follow-up of four years, 76

| Full text

July 2008 Br J Cardiol 2008;15:210-14

Clinical experience with prolonged-release nicotinic acid in statin-treated patients managed in Ireland

Michael O’Reilly, Ulrike Hostalek, John Kastelein

Abstract

Introduction Cardiovascular events remain the leading cause of morbidity and mortality in developed countries, and the treatment of dyslipidaemia is central to the overall management of cardiovascular risk.1,2Although correction of hypercholesterolaemia remains the principal target for correction of the lipid profile, dyslipidaemia is heterogeneous in presentation, with many patients presenting with low high-density lipoprotein-cholesterol (HDL-C) in addition to elevated concentrations of ApoB-containing lipoproteins. A survey carried out in 11 European countries identified low HDL-C (<1.03 mmol/L in men and <1.29 mmol/L in women) in ab

| Full text

For healthcare professionals only

Add Banner

Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now